Physician profile
Ryan Scott Rafa
NPI 1124663232
$6,798.14
in general payments reported to CMS, 2019-2025
21 companies · $973 in 2025
The $973 reported for 2025 was more than what 83% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $197 · 2022: $770 · 2023: $2,826 · 2024: $2,032 · 2025: $973.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,976 · Travel and Lodging: $723 · Education: $132.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,976.22 |
| Travel and Lodging | $722.90 |
| Education | $132.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $1,215.31 | 2023-2025 | Spravato |
| Abbvie INC. | $1,159.13 | 2021-2025 | |
| Axsome Therapeutics, INC. | $1,011.66 | 2023-2025 | Auvelity, Sunosi |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $593.56 | 2022-2025 | Caplyta |
| Alkermes, INC. | $469.56 | 2023-2025 | Aristada, Lybalvi, Vivitrol |
| Neuronetics, INC. | $452.31 | 2022-2024 | Neurostar Tms Therapy System |
| Teva Pharmaceuticals USA, INC. | $445.42 | 2022-2025 | Austedo Xr, Austedo, Austedo Xr |
| Neurocrine Biosciences, INC. | $207.13 | 2021-2025 | Ingrezza |
| Otsuka America Pharmaceutical, INC. | $200.69 | 2021-2025 | Rexulti, Nuedexta, Abilify Asimtufii |
| Indivior INC. | $180.90 | 2021-2024 | Sublocade |
| Sunovion Pharmaceuticals INC. | $131.03 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $128.83 | 2021-2025 | Trintellix |
| Almatica Pharma LLC | $120.06 | 2023-2025 | Loreev Xr |
| Avanir Pharmaceuticals, INC. | $90.90 | 2021-2022 | |
| Corium, LLC | $70.44 | 2023-2024 | Azstarys |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $69.80 | 2023-2024 | Jornay Pm |
| Lundbeck LLC | $65.94 | 2022 | |
| Vanda Pharmaceuticals INC. | $59.30 | 2024-2025 | Fanapt |
| Neos Therapeutics, LP | $54.96 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $50.21 | 2025 | Cobenfy |
| Hikma Pharmaceuticals USA | $21.00 | 2023 | Kloxxado |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Rafa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.